Patient characteristics
| . | AML . | ALL . |
|---|---|---|
| N = 3793 . | N = 2213 . | |
| Median age at HCT, y (range) | 49 (16-74) | 42 (16-76) |
| Age, category | ||
| <50 | 1927 (50.8) | 1494 (67.5) |
| ≥50 | 1866 (49.2) | 719 (32.5) |
| Sex match between recipient and donor | ||
| Female to male | 781 (20.6) | 456 (20.6) |
| Others | 3012 (79.4) | 1757 (79.4) |
| Recipient/donor CMV serostatus | ||
| Negative/Positive | 351 (9.3) | 256 (11.6) |
| Positive/Negative | 1367 (36.0) | 781 (35.3) |
| Positive/Positive | 2075 (54.7) | 1176 (53.1) |
| DRI | ||
| Low | 549 (14.5) | 0 (0.0) |
| Intermediate | 3046 (80.3) | 1927 (87.1) |
| High | 198 (5.2) | 286 (12.9) |
| Disease status | ||
| First complete remission | 2797 (73.7) | 1927 (87.1) |
| Second complete remission | 996 (26.3) | 286 (12.9) |
| HCT-CI | ||
| <2 | 2910 (76.7) | 1762 (79.6) |
| ≥2 | 883 (23.3) | 451 (20.4) |
| Donor source | ||
| HLA matched related | 1031 (27.2) | 663 (30.0) |
| HLA 1-antigen-mismatched related | 106 (2.8) | 52 (2.3) |
| HLA matched unrelated | 1070 (28.2) | 616 (27.8) |
| HLA mismatched unrelated | 978 (25.8) | 565 (25.5) |
| Umbilical cord blood | 402 (10.6) | 212 (9.6) |
| Haploidentical | 206 (5.4) | 105 (4.7) |
| Conditioning intensity | ||
| Myeloablative | 2863 (75.5) | 1669 (75.4) |
| Reduced intensity | 930 (24.5) | 544 (24.6) |
| GVHD prophylaxis | ||
| CSA-based | 1241 (32.7) | 779 (35.2) |
| TAC-based | 2552 (67.3) | 1434 (64.8) |
| In vivo T-cell depletion | ||
| No | 3489 (92.0) | 2055 (92.9) |
| Yes | 304 (8.0) | 158 (7.1) |
| Median y of HCT, (range) | 2013 (2006-2019) | 2013 (2006-2019) |
| Year of HCT | ||
| 2006-2012 | 1629 (42.9) | 976 (44.1) |
| 2013-2019 | 2164 (57.1) | 1237 (55.9) |
| Ph-chromosome | ||
| Ph-chromosome negative | - | 1283 (58.0) |
| Ph-chromosome positive | - | 930 (42.0) |
| Grades 2-4 Acute GVHD by day 65 | ||
| No | 2522 (66.5) | 1371 (62.0) |
| Yes | 1271 (33.5) | 842 (38.0) |
| Grades 3-4 acute GVHD by day 65 | ||
| No | 3463 (91.3) | 2015 (91.1) |
| Yes | 330 (8.7) | 198 (8.9) |
| CMV reactivation by day 65 | ||
| No | 1929 (50.9) | 1167 (52.7) |
| Yes | 1864 (49.1) | 1046 (47.3) |
| . | AML . | ALL . |
|---|---|---|
| N = 3793 . | N = 2213 . | |
| Median age at HCT, y (range) | 49 (16-74) | 42 (16-76) |
| Age, category | ||
| <50 | 1927 (50.8) | 1494 (67.5) |
| ≥50 | 1866 (49.2) | 719 (32.5) |
| Sex match between recipient and donor | ||
| Female to male | 781 (20.6) | 456 (20.6) |
| Others | 3012 (79.4) | 1757 (79.4) |
| Recipient/donor CMV serostatus | ||
| Negative/Positive | 351 (9.3) | 256 (11.6) |
| Positive/Negative | 1367 (36.0) | 781 (35.3) |
| Positive/Positive | 2075 (54.7) | 1176 (53.1) |
| DRI | ||
| Low | 549 (14.5) | 0 (0.0) |
| Intermediate | 3046 (80.3) | 1927 (87.1) |
| High | 198 (5.2) | 286 (12.9) |
| Disease status | ||
| First complete remission | 2797 (73.7) | 1927 (87.1) |
| Second complete remission | 996 (26.3) | 286 (12.9) |
| HCT-CI | ||
| <2 | 2910 (76.7) | 1762 (79.6) |
| ≥2 | 883 (23.3) | 451 (20.4) |
| Donor source | ||
| HLA matched related | 1031 (27.2) | 663 (30.0) |
| HLA 1-antigen-mismatched related | 106 (2.8) | 52 (2.3) |
| HLA matched unrelated | 1070 (28.2) | 616 (27.8) |
| HLA mismatched unrelated | 978 (25.8) | 565 (25.5) |
| Umbilical cord blood | 402 (10.6) | 212 (9.6) |
| Haploidentical | 206 (5.4) | 105 (4.7) |
| Conditioning intensity | ||
| Myeloablative | 2863 (75.5) | 1669 (75.4) |
| Reduced intensity | 930 (24.5) | 544 (24.6) |
| GVHD prophylaxis | ||
| CSA-based | 1241 (32.7) | 779 (35.2) |
| TAC-based | 2552 (67.3) | 1434 (64.8) |
| In vivo T-cell depletion | ||
| No | 3489 (92.0) | 2055 (92.9) |
| Yes | 304 (8.0) | 158 (7.1) |
| Median y of HCT, (range) | 2013 (2006-2019) | 2013 (2006-2019) |
| Year of HCT | ||
| 2006-2012 | 1629 (42.9) | 976 (44.1) |
| 2013-2019 | 2164 (57.1) | 1237 (55.9) |
| Ph-chromosome | ||
| Ph-chromosome negative | - | 1283 (58.0) |
| Ph-chromosome positive | - | 930 (42.0) |
| Grades 2-4 Acute GVHD by day 65 | ||
| No | 2522 (66.5) | 1371 (62.0) |
| Yes | 1271 (33.5) | 842 (38.0) |
| Grades 3-4 acute GVHD by day 65 | ||
| No | 3463 (91.3) | 2015 (91.1) |
| Yes | 330 (8.7) | 198 (8.9) |
| CMV reactivation by day 65 | ||
| No | 1929 (50.9) | 1167 (52.7) |
| Yes | 1864 (49.1) | 1046 (47.3) |
DRI, disease risk index; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; CSA, cyclosporine; TAC, tacrolimus.